Dr. Tamara Lotan is a urologic pathologist who studies how oncogenic signaling pathways regulate epithelial morphogenesis during embryonic development and tumorigenesis. Using novel transgenic mouse models combined with human tumor tissue samples, Dr. Lotan is defining the roles of these critical signals in epithelial development and tumor progression.
Dr. Lotan is a urologic pathologist who studies how oncogenic signaling pathways regulate epithelial morphogenesis during embryonic development and tumorigenesis. Her basic research focuses on the role of PTEN/PI3K/mTOR signaling in a number of epithelial systems (prostate, breast and skin), and is principally directed towards understanding how these oncogenic signaling pathways affect epithelial differentiation, cell adhesion and migration using transgenic mouse models.
The translational research program in her lab has centered on the analytic, pre-analytic and clinical validation of a number of tissue-based biomarkers in prostate cancer which are useful for molecular classification of prostate tumors and which may serve as prognostic and/or predictive biomarkers. Her lab is best known for its work on PTEN, the most commonly lost tumor suppressor in prostate cancer and the most prevalent molecular alteration associated with patient outcomes in the disease. Working collaboratively with national and international groups, the lab completed genetic validation of this assay in more than 5000 prostate tumors, and it is now used in CLIA-accredited laboratories and routinely in clinical surgical pathology at Johns Hopkins. In parallel, the Lotan lab has also worked on highly validated assays to assess additional tumors suppressors, including TP53, RB1 and MSH2 mutational status in prostate cancer. The lab also has an active interest in prostate cancer health disparity research.
View all on Pubmed
Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM. PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients. Clinical Cancer Research 2011; 17(20):6563-73.
Tan H, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, Mosier S, Gocke CD, Epstein JI, Netto GJ, Liu W, Isaacs WB, De Marzo AM, Lotan TL. Rb Loss is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma. Clinical Cancer Research 2014; 20(4):890-903.
Ahearn TU, PetterssonA, Ebot EM, Gerke T, Morais CL, Hicks J, Wilson KM, RiderJR, Sesso HD,Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA*, Lotan TL*. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. JNCI 2016; 108(2). *Equal Contribution
Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris S, Hicks JL, Eisenberger MA, De Marzo AM, Epstein JI, Isaacs WB, Eshleman JR, Pritchard CC, Lotan TL. MSH2 Loss in Primary Prostate Cancer. Clinical Cancer Research 2017; 23(22):6863-6874.
Asrani K, Sood A, Torres A, Georgess D, Phatak P, Kaur H, Dubin A, Talbot CC Jr, Elhelu L, Ewald AJ, Xiao B, Worley P, Lotan TL. mTORC1 Loss Impairs Epidermal Adhesion via TGF-β/Rho kinase activation. Journal of Clinical Investigation 2017; 127(11):4001-4017.